Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome

Phase 3

Terminated

Conditions: Prader-willi Syndrome

Interventions: Drug: placebo
Drug: rimonabant

First Posted Date: 2008-01-28

Last Posted Date: 2023-03-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 10

Registration Number: NCT00603109

Locations: 🇺🇸
New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, United States

Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease

Not Applicable

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Depression

Interventions: Behavioral: PID-C
Behavioral: Problem Solving-Rx Adherence (PSA)

First Posted Date: 2008-01-25

Last Posted Date: 2016-07-15

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 101

Registration Number: NCT00601055

Locations: 🇺🇸
The Burke Rehabilitation Hospital, White Plains, New York, United States
🇺🇸
Weill Medical College of Cornell University, White Plains, New York, United States

Application and Evaluation of Transference Focused Psychotherapy Modified for Adolescents

Not Applicable

Conditions: Behavior Problems
Identity Pathology

Interventions: Behavioral: Individual Psychotherapy
Behavioral: Psychotherapy

First Posted Date: 2007-12-12

Last Posted Date: 2011-01-04

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT00571571

Locations: 🇺🇸
New York-Presbyterian Hospital, White Plains, New York, United States

Evaluating the Impact on Quality and Costs of Regional Clinical Data Exchange Programs in New York State

Completed

Conditions: Quality of Health Care
Health Care Costs

Interventions: Other: Health information technology and exchange

First Posted Date: 2007-12-12

Last Posted Date: 2017-02-23

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 218766

Registration Number: NCT00571376

Locations: 🇺🇸
Rochester RHIO, Rochester, New York, United States

Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis

Early Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Drug: arsenic trioxide
Drug: cytarabine

First Posted Date: 2007-12-12

Last Posted Date: 2017-03-03

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 21

Registration Number: NCT00572065

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers

Not Applicable

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Dietary Supplement: Group 2
Dietary Supplement: Group 1

First Posted Date: 2007-11-29

Last Posted Date: 2017-05-25

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 46

Registration Number: NCT00565214

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Effectiveness of Case Management Versus Case Management Plus Problem-solving Therapy to Treat Depression in Low-income Elders

Not Applicable

Completed

Conditions: Depression

Interventions: Behavioral: Problem-solving therapy (PST)
Behavioral: Case management (CM)

First Posted Date: 2007-10-08

Last Posted Date: 2014-12-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 187

Registration Number: NCT00540865

Locations: 🇺🇸
Weill Medical College of Cornell University, White Plains, New York, United States
🇺🇸
University of California - San Francisco, San Francisco, California, United States

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2007-10-03

Last Posted Date: 2011-06-30

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 30

Registration Number: NCT00538876

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: thalidomide
Drug: lenalidomide

First Posted Date: 2007-10-03

Last Posted Date: 2018-06-06

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 5

Registration Number: NCT00538824

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: thalomid
Drug: lenalidomide
Drug: clarithromycin
Drug: dexamethasone

First Posted Date: 2007-10-03

Last Posted Date: 2021-05-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 26

Registration Number: NCT00538733

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy